Counseling patients with higher-risk MDS regarding survival with azacitidine therapy: are we using realistic estimates?

Blood Cancer J. 2018 Jun 11;8(6):55. doi: 10.1038/s41408-018-0081-8.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Azacitidine / administration & dosage
  • Azacitidine / therapeutic use*
  • Clinical Trials as Topic
  • Counseling*
  • Female
  • Follow-Up Studies
  • Humans
  • Male
  • Middle Aged
  • Myelodysplastic Syndromes / diagnosis
  • Myelodysplastic Syndromes / drug therapy*
  • Myelodysplastic Syndromes / mortality*
  • Prognosis
  • Treatment Outcome

Substances

  • Azacitidine